A groundbreaking microfluidics platform, UQ-Surf, developed by researchers at the University of QueenslandS Australian Institute for Bioengineering and Nanotechnology (AIBN), is poised to transform regenerative medicine and tissue engineering. This technology facilitates the efficient production of microgel droplets,which serve as tiny,temperature-sensitive environments for housing living biological material. This advancement represents a significant leap in the scalable and biocompatible fabrication of smart materials for medical uses.

Microfluidics involves manipulating fluids at a microscale, granting exceptional control over the physical and chemical surroundings of substances.This precise control is vital in regenerative medicine, enabling researchers to explore and optimize the behavior of cells, biomaterials, and therapeutic agents in highly specific ways.UQ-surf capitalizes on this principle to generate thousands of microgel droplets per minute, each acting as a customizable microenvironment.

A key feature of the UQ-Surf platform is its ability to produce microgels that respond to temperature variations. Unlike conventional microgel fabrication methods that frequently enough involve complex chemical treatments and multiple steps, UQ-Surf employs a simplified approach. The droplets can be activated or modified simply by adjusting the surrounding temperature. This not only accelerates production but also reduces the risk of contamination, making the platform more suitable for clinical and therapeutic applications.

Traditional methods for encapsulating living materials in microgels typically use harsh chemical demulsifiers, which can jeopardize the viability of sensitive biological contents. The UQ-Surf platform eliminates the need for such treatments, reducing potential cytotoxicity and ensuring better preservation of the encapsulated materials. By removing harmful solvents and processing steps, the technology enables researchers to produce microgels that are both functional and safe for medical applications.

The platform’s versatility unlocks possibilities across various domains within biomedical science. For instance,in drug revelation,UQ-Surf could be used to construct sophisticated 3D in vitro models that mimic human tissue. These models can aid pharmaceutical researchers in testing how drugs interact with biological systems in controlled environments. Similarly, the ability to encapsulate and release payloads in response to temperature changes makes the system well-suited for targeted drug delivery. Drugs, cells, or genetic material can be loaded into microgel droplets and released precisely when and were they are needed.

In tissue engineering, UQ-Surf holds potential for developing scaffolds that promote tissue regeneration. The controlled release of growth factors or stem cells from the microgels can guide cell behavior and improve the integration of engineered tissues into the body. This could support the repair or replacement of damaged organs and tissues,offering new therapeutic options for conditions that are currently difficult to treat.

UQ-Surf also offers opportunities for scaling up production for industrial and clinical applications. Its high-throughput capability – producing “thousands of uniform microdroplets per minute” – makes it suitable for both laboratory research and eventual commercial manufacturing. The system has already demonstrated proof of concept in laboratory settings, showing both scientific utility and market viability.

The technology has been patented through UniQuest, “the University of Queensland’s commercialisation company,” highlighting its readiness for broader adoption. The global market for microfluidics is expanding rapidly, with projections indicating a near doubling in market value from 2023 to 2028. UQ-Surf positions the university and its collaborators to contribute significantly to this growth by offering a scalable, flexible, and biocompatible tool for a wide array of biomedical applications.

The development of UQ-Surf reflects a multi-institutional collaboration that includes contributions from AIBN researchers and engineers from the UQ School of Mechanical and Mining Engineering, as well as partners from the university of Adelaide, Queensland University of Technology, the National University of Singapore and biotech company Gelomics.